Who Developed Retatrutide?
Short answer: Eli Lilly. Retatrutide carried the development code LY3437943, and the molecule was first described in a 2022 paper by Coskun and colleagues from Lilly in Cell Metabolism, which reported its design and its activity at the GLP-1, GIP and glucagon receptors. The phase 2 obesity trial was published in 2023 and phase 3 trials are ongoing.
Lilly also developed tirzepatide, the dual GIP and GLP-1 agonist, and Retatrutide extends that line by adding glucagon receptor activity. The two molecules are distinct compounds with different sequences.
The code LY3437943 still appears in trial registrations and early papers, so a reader searching the literature needs both the code and the name.
REVIVE LAB UAE supplies the pack for laboratory research use only. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.
Retatrutide Pack 20 mg — REVIVE LAB UAE
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
Research-Use Only Disclaimer: This page is published for laboratory and scientific research information purposes only. Nothing here constitutes medical advice, dosing guidance, or a therapeutic recommendation. Products supplied by REVIVE LAB UAE (revivelab.ae) — where applicable — are sold strictly as reference materials for research use, not for human or veterinary consumption. Buyers and readers are solely responsible for compliance with applicable UAE laws and institutional research ethics requirements.